Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lisa A. Carey

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer

Journal of Clinical Oncology

English

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of Clinical Oncology

English

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Journal of Clinical Oncology

English

Histone Deacetylase 11 Inhibition Promotes Breast Cancer Metastasis From Lymph Nodes

Nature Communications

English

Influence of Provider Factors and Race on Uptake of Breast Cancer Gene Expression Profiling

English

Patient‐Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

English

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

English

Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women

English

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Breast Cancer Research

Cancer Research

Oncology

2020

English

Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

Journal of the American College of Surgeons

Surgery

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Lisa A. Carey

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Histone Deacetylase 11 Inhibition Promotes Breast Cancer Metastasis From Lymph Nodes

Influence of Provider Factors and Race on Uptake of Breast Cancer Gene Expression Profiling

Patient‐Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

Age-Specific Changes in Intrinsic Breast Cancer Subtypes: A Focus on Older Women

TBCRC 002: A Phase II, Randomized, Open-Label Trial of Preoperative Letrozole With or Without Bevacizumab in Postmenopausal Women With Newly Diagnosed Stage 2/3 Hormone Receptor-Positive and HER2-negative Breast Cancer

Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)